Moreover, as the evidence for T2DM therapies in pediatric populations expands, future studies are needed to assess the impact of cointervention types (metformin vs. insulin vs. metformin + insulin), different types of SGLT2i, and the dose effects of SGLT2i. Here, INS is linked to type 2 diabetes mellitus.